Is Apolipoprotein B and Small, Dense low density lipoprotein a better marker of cardiovascular risk?

ABIODUN, I.S.*

Department of Haematology and Blood Transfusion, Babcock University Teaching Hospital, Ilishan-Remo, Ogun state, Nigeria

*Correspondence Info:
ABIODUN, Ifeoluwa Silvanus
Department of Haematology and Blood Transfusion, Babcock University Teaching Hospital, Ilishan-Remo, Ogun state, Nigeria
Telephone: (+234) 816 307 4264
E-mail: ifeoluwasylva@yahoo.com

Abstract

The association between low density lipoprotein cholesterol and cardiovascular risk is well established. However, the measurement of the cholesterol content of this lipoprotein incompletely accounts for the risk of cardiovascular disease. As part of its limitations, LDL cholesterol concentration does not precisely count the number of LDL particles, but Apo B does. The levels of Apolipoprotein B and small dense low density lipoprotein have been shown to be associated with risk of cardiovascular disease. There is one Apo B per LDL particle; hence, LDL-Apo B accurately defines LDL particle number. Also, the ratio of cholesterol to Apo B differs from person to person, thereby explaining why LDL-cholesterol level does not necessarily indicate LDL particle number. Furthermore, Apo B reflects the concentration of potentially atherogenic particles i.e. the total Apo B level is a measure of the total number of lipoprotein particles in LDL, IDL and VLDL (non-HDL cholesterol). This implies that if most Apo B-containing lipoproteins in each fraction are atherogenic, the total concentration of Apo B will indicate cardiovascular risk better than LDL cholesterol level does. A predominance of small, dense, low-density lipoprotein cholesterol particles has been associated with a 3-fold or even greater risk of coronary heart disease in a collection of cross-sectional studies. Recent prospective evidence describes small, dense, low-density lipoprotein cholesterol as predictive of coronary heart disease as most of the traditional risk factors like smoking and elevated blood pressure. Cardiovascular risk is more directly related to the number and sizes of circulating atherogenic particles than to the concentration of cholesterol in these particles; therefore, adopting the traditional lipid profile (Triglyceride, HDL, LDL, total cholesterol etc.) will result in an underestimation of the true atherogenic burden as well as serve as a poor assessment of cardiovascular risk in individuals.

Keywords: Cardiovascular diseases, Low density lipoprotein, Apolipoprotein B, Small dense low density lipoprotein, high density lipoprotein, triglycerides, total cholesterol

1. Introduction

1.1 Burden of cardiovascular diseases

Cardiovascular diseases (CVD) remain leading causes of mortality and morbidity in developed countries and are steadily emerging as a major public health problem in developing countries. The increasing burden of cardiovascular diseases in developing countries has generated concern in recent years. For the better part of the last century, cardiovascular diseases were associated with industrialized and developed countries. However, since the turn of the century, the absolute burden of cardiovascular diseases has been greater in developing countries [1][2].

The Global Burden of Diseases study (2010) associated 66.7% of deaths worldwide with non-communicable diseases, with cardiovascular diseases being responsible for 43% of the deaths. In spite of the total increase in CVD burden, effective preventive and therapeutic burden has led to a decline in the mortality and morbidity associated with cardiovascular diseases in developed countries [4].

In developing countries, on the other hand, the increasing burden of cardiovascular diseases has been identified and attributed to an increase in the prevalence of risk factors triggered by industrialization, rural-urban population drift, urbanization, lack of access to modern medical
intervention etc. [5-8]. However, most of the risk factors can be prevented and chronic conditions managed via modified lifestyles. These risk factors include smoking, sedentary lifestyles, inappropriate dietary habits, glucose intolerance, hypertension, dyslipidemia and obesity.

2. Role of traditional lipid profile in the assessment of cardiovascular risk

Dyslipidemia, alongside with elevated blood pressure/hypertension, abdominal obesity and glucose intolerance/diabetes mellitus, is a component of metabolic syndrome and has been established as a risk factor for cardiovascular disease [9][10]. Other risk factors associated with cardiovascular disease include sedentary lifestyle, male gender, older age, excessive alcohol consumption, smoking as well as family history of cardiovascular diseases [11-15].

Measurement of lipid profile is the most common approach devised in assessing and identifying individuals at risk of cardiovascular diseases [16]. Current clinical guidelines emphasize the estimation of the indices of traditional lipid profile (Total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) in the assessment of cardiovascular risk. Several studies have revealed an inverse relationship between risk of cardiovascular diseases and plasma high density lipoprotein (HDL) levels [17-20]. Other studies have demonstrated a positive correlation between elevated concentrations of total and/or low density lipoprotein cholesterol levels and cardiovascular risk [21-23].

Also, increases in HDL cholesterol alone have also been established to be insufficient in reducing the risk of cardiovascular events [24], thereby implicating serum triglycerides and LDL cholesterol as well as other elements such as Apolipoprotein B levels in the assessment of cardiovascular risk [25].

3. Role of Apolipoprotein Band Small, Dense low density lipoprotein in the assessment of cardiovascular risk

Not only is the present traditional lipid profile approach complex, rather, other indices have been suggested to be better markers in the assessment of cardiovascular risk. The best studied and established of these is the measurement of apolipoprotein B and small, dense low density lipoprotein. Considerable evidence from studies have shown in different clinical scenarios and analytical reasons why ApoB and small, dense LDL may have a greater utility in cardiovascular disease risk assessment.

Apolipoprotein B-100 and small, dense LDL are beneficial markers of cardiovascular disease. Apo B-100 demonstrates the number of LDL particles reflecting atherogenicity better than the LDL cholesterol concentration. On the other hand, small, dense LDL is a lipoprotein subclass that causes atherosclerosis with a much higher risk than large LDL. The results of both apoB-100 or small, dense LDL can be good risk markers of cardiovascular diseases when tested individually, whereas the cause of cardiovascular diseases can be better explained by analyzing them in combination [26].

Firstly, the traditional lipid profile (basically, LDL cholesterol), does not account for all the cardiovascular risk associated with dyslipidemia as a risk factor. As part of its limitations, LDL cholesterol concentration does not precisely count the number of LDL particles, but Apo B does. There is one Apo B per LDL particle; hence, LDL-Apo B accurately defines LDL particle number. Also, the ratio of cholesterol to Apo B differs from person to person, thereby explaining why LDL-cholesterol level does not necessarily indicate LDL particle number [27].

Furthermore, Apo B reflects the concentration of potentially atherogenic particles [28] i.e. the total Apo B level is a measure of the total number of lipoprotein particles in LDL, IDL and VLDL (non-HDL cholesterol). This implies that if most Apo B-containing lipoproteins in each fraction are atherogenic, the total concentration of Apo B will indicate cardiovascular risk better than LDL cholesterol level does [29]. Also, several studies have revealed that the total cholesterol content of non-HDL cholesterols correlates strongly with total Apo B levels [27][30], with several investigators also suggesting that non-HDL cholesterol better represents atherogenic cholesterol than LDL cholesterol[27][30][31].

Apo B, which is present in VLDL, IDL, large buoyant LDL and small, dense LDL, reflects the total number of atherogenic particles [32], i.e. the total number of ApoB-containing lipoprotein particles [33]. Elevated Apo B levels may indicate an increased number of small, dense LDL particles which are prone to oxidation, promote inflammatory responses as well as plaque formation [34].

Furthermore, measurement of Apo B concentration comes with an advantage- the concentration of apolipoproteins do not change after meals, neither do they change during different times of the day. This remains an advantage in comparison...
with the traditional lipid profile which is best estimated while the subjects are observing a 10-14 hour fast. Another advantage of estimating Apolipoprotein levels is that they are better markers, when compared to traditional lipid measures, of coronary heart disease risk in patients taking lipid-lowering treatment.

On the other hand, the published data hasn’t been totally consistent as some other studies have revealed that ApoB and Apo A-1 did not perform better, when compared with traditional lipid profile, thereby triggering a debate [35-40]. The global INTERHEART study of risk factors for acute myocardial infarction in 52 countries however concluded that ‘the Apo B/A-1 ratio was the most important risk factor for all geographic regions’.

Low density lipoproteins comprises heterogeneous particles characterized by varying sizes, chemical compositions, densities, physiologic properties and atherogenic properties i.e. all LDL are not created equally. Large buoyant LDL represents the good LDL responsible for the transport of cholesterol to peripheral tissues for cell membrane maintenance, bile acid synthesis by the liver and for the production of steroidal hormones.

Small dense LDL is a component of the lipid triad associated with atherogenic dyslipidemia and has been demonstrated in several clinical studies to be an independent risk factor for cardiovascular disease [41]. Also, the Small Dense Low Density Lipoprotein cholesterol: low density lipoprotein cholesterol ratio plays a vital role in the determination of cardiovascular risk [42].

A predominance of small, dense, low-density lipoprotein cholesterol particles has been associated with a 3-fold or even greater risk of coronary heart disease in a collection of cross-sectional studies, even at ‘normal’ concentrations of LDL cholesterol [43][44]. Furthermore, the QUEBEC cardiovascular study demonstrated the association between coronary heart disease and a prevalence of small, dense LDL in the first seven years of its follow-up [45].

Recent prospective evidence describes small, dense, low-density lipoprotein cholesterol as predictive of coronary heart disease as most of the traditional risk factors like smoking and elevated blood pressure [46][47]. Koba et al[48] (2006), on the other hand, specified that a progression of coronary heart disease was associated with the concentration of small, dense LDL and not the size of the LDL particles.

There are several credible biochemical mechanisms implicating small dense low density lipoprotein cholesterol to be more potentially atherogenic compared to its larger, buoyant and lighter counterparts [49]. Studies have shown small dense LDL particles to be more atherogenic than large buoyant particles, as they are more susceptible to oxidation and have a decreased affinity for LDL receptor [50].

In conclusion, cardiovascular risk is more directly related to the number and sizes of circulating atherogenic particles than to the concentration of cholesterol in these particles [51][52]. Therefore, adopting the traditional lipid profile (Triglyceride, HDL, LDL, total cholesterol etc.) will result in an underestimation of the true atherogenic burden [52] as well as serve as a poor assessment of cardiovascular risk in individuals. However, the question related to the better marker in the assessment of cardiovascular risk remains unanswered.

References

[1] World Health Organization (WHO). Non-communicable diseases country profiles 2011. WHO Geneva Report. Geneva, Switzerland; 2011:1-209
[2] Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation 2005; 112:3562-8.
[3] Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet 2012; 380:2224-60.
[4] Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in southeastern Nigeria. Nig J Cardiol 2013;10:77-80
[5] Taylor R, Jalaludin B, Levy S, Montaville B, Gee K, Sladden T. Prevalence of diabetes, hypertension and obesity at different levels of urbanization in Vanuatu. Med J Aust 1991; 155:86-90.
[6] Drewnoski A, Popkin BM. The nutrition transition: New trends in the global diet. Nutr Rev 1997; 55:31-43.
[7] Van Rooyen JM, Kruger HS, Huisman HW, Wissing MP, Margetts BM, Venter CS et al. An epidemiological study of hypertension and its determinants in a population in transition. The THUSA study. J Hum Hypertension 2000; 14:779-87.
[8] Hakeem R, Thomas J, Badruddin SH. Urbanization and coronary heart disease risk factors in south Asian children. J Pak Med Assoc 2001; 51:22-8.
[9] Lehto M, Tuomi T, Mahtani MM, Widen E, Forsblom C, Sarelín L, Gullstrom M, Isomaa B, Lehtovirta M, Hyyrkko A, Kanninen T, Orho M, Manley S, Turner RC, Brettn T, Kirby A, Thomas J, Duyk G, Lander E, Taskinen MR, Groop L. Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest 1997; 99(4):582-91.

[10] Sarwar N, Danesh J, Eiriksdottir, G, Sigurdsson G, Wareham N, Bingham S, Boekholdt M, Khaw K, Gudnason V. Triglycerides and the risk of coronary heart disease: 10.158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007; 115:450-458.

[11] Howard, BV; Wylie-Rosett, J. Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association." Circulation 2002; 106 (4): 523–7.

[12] Bridget BK, Fuster V (2010). Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, D.C: 2010. National Academies Press.

[13] Shanthi M, Pekka P, Bo N. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization, 2011.

[14] Finks SW, Airee A, Chow SL, Macaulay TE, Moranville MJ, Rogers KC, Trujillo TC, Key articles of dietary interventions that influence cardiovascular mortality. Pharmacotherapy 2012; 32 (4): e54–87.

[15] Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes—an updated review of the evidence. Current atherosclerosis reports 2012 14 (6): 515–24.

[16] Benoit JA, Mattijis B, Kastelein JP. Lipid parameters for measuring risk of cardiovascular diseases. Nature Reviews Cardiology 2011; 8:197-206

[17] Gordon DJ and Rifkind BM. High-density lipoprotein- the clinical implications of recent studies. N Engl J Med 1989; 321(19):1311-6.

[18] Manninen V, Tenkanen L, Koskinen P, Huttinen JK, Manttari M, Heinonen OP et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.

[19] Navab M, Berliner JA, Watson AD, Hama SY, Territo, MC, Luisis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. ArteriosclerThrombVascBiol 1996; 16:831-842.

[20] Stein O, Stein Y. Atheroprotective mechanisms of HDL. Arteriosclerosis 1999; 144:285-301.

[21] Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. Eur. J. Prev. Cardiol1996; 3: 213–219.

[22] Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardio1999; 83: 13–16.

[23] Shankar A, Mitchell P, Rochtchina E, Wang J. The association between circulating while blood cell count, triglyceride level and cardiovascular and all-cause mortality: Population-based cohort study. Atherosclerosis2007; 192: 177–183.

[24] Briel M, Ferreira-Gonzalez I, You JI, Karanicolas PJ, Aki EA, Wu P, Blechacz B, Assler D, Wei X, Sharan A et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. Brit Med J2009; 338.

[25] Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stamper MJ, Pfeffer MA, Braunwald E, VLDL, apolipoproteins B, CHD, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation2000; 102: 1886–1892.

[26] Ito MK. Dyslipidemia: management using optimal lipid-lowering therapy. Ann Pharmacother 2012; 46:1368-1381.

[27] Abate N, Vega GI, Grundy SM. Variability in cholesterol content and physical proportions of lipoproteins containing apolipoprotein B-100. Atherosclerosis1993; 104: 159-171.

[28] Shlipasree AS, Sahu R, Murthy J, & Kumar K. A Study of Serum Apolipoprotein A1, Apolipoprotein B and Lipid Profile in Stroke. Journal of Clinical and Diagnostic Research 2013; 7(7): 1303–1306.

[29] Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non–HDL cholesterol reporting in lipid management. J Clin Lipidol2008; 2: 267–273

[30] Vega GI, Grundy SM. Does measurement of apolipoprotein B have place in cholesterol management? Arteriosclerosis1990; 10: 668-671.

[31] Havel RJ, Rapport F. Management of primary hyperlipidemia. N Engl J Med1995; 332: 1491-1498

[32] Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res1998; 29:1461-1473.

[33] Mudd JO, Borlaug BA, Johnston PV, Krall BG, Rouf R, Blumenthal RS, Kwaterovich PO. Beyond low-density cholesterol: defining the
role of low density lipoprotein heterogeneity in coronary artery disease. *Journal of American College of Cardiology* 2007; 50:18

[34] Shilpasree, A.S., Sahukar, S., Murthy, J., & Kumar, K. (2013). A Study of Serum Apolipoprotein A1, Apolipoprotein B and Lipid Profile in Stroke. *Journal of Clinical and Diagnostic Research* 2013; 7(7), 1303–1306.

[35] Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catelier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-1 and B, and HDL density subfractions- the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2001; 104:1108-1113.

[36] Shai I, Rimm EB, Schulze MB, Rifai N, Stampfer MJ, Hu FB. Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. *Diabetologia* 2004; 47:1760-7

[37] Denke MA. Weighing before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. *Circulation* 2005; 112(22):3368-70

[38] Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol. *Circulation* 2005; 112:3366-3367.

[39] Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL Cholesterol, Apolipoproteins A-1 and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. *JAMA* 2005; 294:326–33.

[40] Van der Steeg WA, Boekholdt SM, El-HArchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwijnderman AH, Kastelein JJ, Khaw KT. Role of the apolipoprotein B–Apolipoprotein A-1 ratio in cardiovascular risk assessment: a case control analysis in EPIC-Norfolk. *Ann Intern Med* 2007; 146(9):640-8.

[41] National Cholesterol Education Programme/Adult Treatment Panel III (NCEP/ATP III). Third report of the National Cholesterol Education Programme (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. *Circulation* 2002; 106:3143.

[42] Khan MS. Small dense Low Density Lipoprotein: new marker for cardiovascular risk and its therapeutic inflection. *Biochem Anal Biochem* 2012; 1(6): 1-4

[43] Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein sub-class patterns and risk of myocardial infarction. *JAMA* 1988; 260: 1917-21.

[44] Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ & Shepherd J.Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. *Atherosclerosis* 1994; 106:241-253.

[45] St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. *ArteriosclerThrombVascBiol* 2005;25:553–9

[46] Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG. Get al. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. *J Am Med Assoc* 1996; 276:882-888

[47] Gardner CD, Fortmann SP, Krauss RM. Association of small, low density lipoprotein particles with the incidence of coronary artery disease in men and women. *J Am Med Assoc* 1996; 276:875-81

[48] Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y et al. Significance of small, dense low density lipoprotein cholesterol concentrations in relation to the severity of coronary heart diseases. *Atherosclerosis* 2006; 189:206-214

[49] Griffin, BA. Lipoprotein atherogenicity: an overview of current mechanisms. Macronutrient Group Symposium on ‘Dietary determinants of lipoprotein-mediated cardiovascular risk’. *Proceedings of the Nutrition Society* 1999; 58: 163–169.

[50] Austin MA, Edwards KL. Small dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. *Curropinlipidol 1996; 7(3):167-71

[51] Barter PJ, Ballantyne, CM, Carnena R et al. Apo B Versus Cholesterol in Estimating Cardiovascular Risk and in Guiding Therapy: Report of the Thirty-Person/Ten Country Panel. *J Intern Med* 2006; 259: 247-258.

[52] Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. *Circulation* 2006; 113: 20-29.